Synthesis and Biological Evaluation of Novel 2-Arylalkylthio-5-iodine-6-substituted-benzyl-pyrimidine-4(3H)-ones as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors

Liang Zhang 1, Xiaowan Tang 1, Yuanyuan Cao 1, Shaotong Wu 1, Yu Zhang 1, Jianxiong Zhao 1, Ying Guo 1, Chao Tian 1, Zhili Zhang 1, Junyi Liu 1,2,* and Xiaowei Wang 1,*

1 Department of Chemical Biology, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China
2 State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing 100191, China

* Authors to whom correspondence should be addressed; E-Mails: jyliu@bjmu.edu.cn (J.L.); xiaoweiwang@bjmu.edu.cn (X.W.); Tel.: +86-10-8280-5203 (X.W.); Fax: +86-10-8280-1706 (X.W.).

Received: 30 April 2014; in revised form: 26 May 2014 / Accepted: 28 May 2014 / Published: 30 May 2014

Abstract: A novel series of 2-arylalkylthio-5-iodine-6-substituted-benzyl-pyrimidine-4(3H)-ones (S-DABOs) 8a–x had been synthesized via an efficient method. Their biological activity against HIV virus and RT assay were evaluated. Some compounds, especially 8h, 8l and 8n, displayed promising activity against HIV-1 RT with IC50 values in a range of 0.41 μM to 0.71 μM, which were much better than that of nevirapine. Molecular modeling studies revealed that the binding mode would be affected via forming an additional hydrogen bond by incorporating an oxygen atom on the C-2 side chain. The biological activity was in accordance with the docking results.

Keywords: HIV; NNRTIs; S-DABOs; IC50; docking

1. Introduction

The reverse transcriptase (RT) of HIV-1, being an essential enzyme in the replication of the virus, is recognized as a great potential target for designing antiretroviral drugs [1]. In recent years, enormous efforts have been made to develop RT inhibitors. In particular, the non-nucleoside reverse transcriptase inhibitors (NNRTIs), a class of components of HAART, have received special attention due to their unique antiviral potency with generally low toxicity and favorable pharmacokinetic properties [2,3].
So far, five NNRTIs drugs—nevirapine, delavirdine, efavirenz, etravirine and rilpivirine (Figure 1)—have been approved for clinical use [4]. However, the high mutation rate of HIV-1 RT and the rapid emergence of drug resistance has limited the therapeutic efficacy of NNRTIs and this necessitates the continued discovery and development of drugs with novel mechanisms of action [5].

**Figure 1.** Structures of NNRTI drugs.

Sulfo-dihydro-alkylthio-benzyl-oxopyrimidines (S-DABOs) as representative NNRTIs [6,7], show their activity not only on HIV-1 wild type, but also on HIV-1 mutants [8]. By studying the crystal structures of different kinds of NNRTIs, it’s found that S-DABOs share the same binding mode as that of TNK-651. They interact with the binding site composed by Tyr181, Tyr188 and Trp229 residues, which is near the catalytic site of the RT. The N-3-H of S-DABOs forms a crucial hydrogen bond with Lys101 inside the hydrophobic pocket. In addition, the molecular may rotate to a butterfly-like conformation so that the crucial hydrophobic forces can be formed between the aryl moiety at C-2 and C-6 and the amino acid residues such as Tyr181, Tyr188, Phe227 [9–14].

Based on these promising results, some modifications were performed to achieve more active S-DABO derivatives. It was anticipated that an oxygen atom on the C-2 side chain would form an additional hydrogen bond, and extending the $\pi$-$\pi$ conjugated system by introducing electron withdrawing groups at the para position of the phenyl ring could be beneficial for the activity [15]. Moreover, optimization in the C-6 phenylmethyl ring at the meta positions would lead to closer interactions with the non-nucleoside binding pocket (NNBP). On the basis of our previous results [16,17], the halogen atom on C-5 position could form an interaction with the carbonyl of Tyr181, which played an important role in improving anti-HIV-1 activity.

Herein, in order to verify the relationship between structure and activity of the target compounds, we synthesized a series of 2-arylalkylthio-5-iodine-6-substitutedbenzyl-pyrimidine-4(3H)-ones 8a–x (Figure 2), and evaluated their inhibitory activity on HIV-1 RT and HIV-1SF33 in TZM-bl cell lines.
2. Results and Discussion

2.1. Chemistry

A general synthetic route to the target compounds is outlined in Scheme 1. The β-ketoesters 5 were prepared via phenylacetyl chloride and Meldrum’s acid without substituents on the phenyl ring [18,19]. Alternatively, for the compounds with dimethyl or difluoro m-substituents on the aromatic moiety, the corresponding compound 5 was generally obtained by reaction of the appropriate substituted benzyl cyanide with zinc and ethyl 2-bromoacetate using the method of Hannick and Kishi [20]. Condensation of 5 with thiourea in the presence of sodium ethoxide in boiling ethanol provided the 6-aryl thiouracils 6. The S-DABOs analogues 7a–x were prepared by S-alkylation using the appropriate substituted alkyl halide and potassium carbonate in anhydrous DMF or sodium ethoxide in ethanol [21–23]. Subsequent treatment of 7a–u with I2 and (NH4)2Ce(NO3)6 (CAN) in refluxing CH3CN afforded the corresponding target compounds 8a–u [24]. Alternatively, another iodination method with NIS in DMF at 0 °C led to target compounds 8v–x [25]. The structure assignments of these compounds were verified by NMR and mass spectral data.

Scheme 1. Synthesis of Target Compounds 8a–x.

Reagents and conditions: (a) acetone, acetic anhydride, con.H2SO4, rt; (b) PhCH2COCl, pyridine, CH2Cl2, ice bath; (c) EtOH, reflux; (d) m-difluoro/m-dimethyl benzyl cyanide, Zn/THF, reflux; (e) thiourea, EtONa/EtOH, reflux; (f) substituted alkyl halide, K2CO3, rt; (g) I2, CAN, reflux; (h) substituted alkyl halide, MeONa/MeOH, rt; (i) NIS, DMF, ice bath.
2.2. Biological Evaluation

All target compounds were evaluated as inhibitors of HIV-1 RT and some active compounds were evaluated for anti-HIV-1_{SF33} activity in the TZM-bl cell line with nevirapine and TNK-651 as reference compounds (Tables 1 and 2) [26]. The biological results revealed that some compounds had potent activity and exhibited obvious structure-activity relationships.

Table 1. Inhibitory Activity of 7a–8x against HIV-1 RT a.

| Compd. | R_1  | R_2                  | IC_{50} b µM | Compd. | R_1  | R_2                  | IC_{50} b µM |
|--------|------|----------------------|--------------|--------|------|----------------------|--------------|
| 7a     | H    | C_6H_5(p-NO_2)CH_2   | >100         | 8a     | H    | C_6H_5(p-NO_2)CH_2   | 9.20         |
| 7b     | CH_3 | (p-NO_2)C_6H_5CH_2   | 3.32         | 8b     | CH_3 | (p-NO_2)C_6H_5CH_2   | 1.66         |
| 7c     | F    | (p-NO_2)C_6H_5CH_2   | >100         | 8c     | F    | (p-NO_2)C_6H_5CH_2   | 5.50         |
| 7d     | (p-CN)C_6H_5CH_2 | >100         | 8d     | (p-CN)C_6H_5CH_2 | 10.62    |
| 7e     | (p-CN)C_6H_5CH_2 | 29.63        | 8e     | (p-CN)C_6H_5CH_2 | 4.03      |
| 7f     | F    | (p-CN)C_6H_5CH_2   | 15.77        | 8f     | F    | (p-CN)C_6H_5CH_2   | 4.49         |
| 7g     | (p-CH_3CO)C_6H_5CH_2 | 55.00   | 8g     | (p-CH_3CO)C_6H_5CH_2 | 13.81    |
| 7h     | CH_3 | (p-CH_3CO)C_6H_5CH_2 | 17.04       | 8h     | CH_3 | (p-CH_3CO)C_6H_5CH_2 | 0.41         |
| 7i     | F    | (p-CH_3CO)C_6H_5CH_2 | 33.92       | 8i     | F    | (p-CH_3CO)C_6H_5CH_2 | 4.03         |
| 7j     | (p-CH_3OOCC)C_6H_5CH_2 | >100    | 8j     | (p-CH_3OOCC)C_6H_5CH_2 | 3.64      |
| 7k     | CH_3 | (p-CH_3OOCC)C_6H_5CH_2 | 7.50        | 8k     | CH_3 | (p-CH_3OOCC)C_6H_5CH_2 | 1.11         |
| 7l     | F    | (p-CH_3OOCC)C_6H_5CH_2 | >100        | 8l     | F    | (p-CH_3OOCC)C_6H_5CH_2 | 0.71         |
| 7m     | H    | (p-NO_2)C_6H_5CH_2   | 67.24        | 8m     | H    | (p-NO_2)C_6H_5CH_2   | 8.64         |
| 7n     | CH_3 | (p-NO_2)C_6H_5CH_2   | 1.40         | 8n     | CH_3 | (p-NO_2)C_6H_5CH_2   | 0.70         |
| 7o     | F    | (p-NO_2)C_6H_5CH_2   | 18.14        | 8o     | F    | (p-NO_2)C_6H_5CH_2   | 6.88         |
| 7p     | (p-NO_2)C_6H_5OCH_2 | 4.58     | 8p     | (p-NO_2)C_6H_5OCH_2 | 6.28      |
| 7q     | CH_3 | (p-NO_2)C_6H_5OCH_2 | 0.59         | 8q     | CH_3 | (p-NO_2)C_6H_5OCH_2 | 1.31         |
| 7r     | F    | (p-NO_2)C_6H_5OCH_2 | 1.31         | 8r     | F    | (p-NO_2)C_6H_5OCH_2 | 2.56         |
| 7s     | H    | C_6H_5OCH_2CH_2      | 16.70        | 8s     | H    | C_6H_5OCH_2CH_2      | 5.88         |
| 7t     | CH_3 | C_6H_5OCH_2CH_2      | 2.64         | 8t     | CH_3 | C_6H_5OCH_2CH_2      | 12.92        |
| 7u     | F    | C_6H_5OCH_2CH_2      | 14.42        | 8u     | F    | C_6H_5OCH_2CH_2      | 18.03        |
| 7v     | H    | C_6H_5OCH_2CH_2      | 12.88        | 8v     | H    | C_6H_5OCH_2CH_2      | 10.20        |
| 7w     | CH_3 | C_6H_5OCH_2CH_2      | 1.82         | 8w     | CH_3 | C_6H_5OCH_2CH_2      | 8.75         |
| 7x     | F    | C_6H_5OCH_2CH_2      | 5.46         | 8x     | F    | C_6H_5OCH_2CH_2      | 1.50         |

a Nevirapine and TNK-651 were used as reference compounds; IC_{50} value for nevirapine and TNK-651 is 6.29 µM and 0.14 µM respectively; b Compound dose (µM) required to inhibit the HIV-1 RT activity by 50%; Data represent mean values of three separate experiments, variation among triplicate samples was less than 15%.

In general, most of the tested compounds displayed activity against HIV-1 RT, and demonstrated a lower IC_{50} than nevirapine within a range of 0.41 µM to 6.28 µM. As shown in Table 1, it was noteworthy that the activity of compounds 8a–o, without an oxygen atom on the C-2 side chain, was much better than that of 7a–o, especially 8h (IC_{50} = 0.41 µM), 8l (IC_{50} = 0.71 µM) and 8n (IC_{50} =
0.70 µM), were about 10-fold more active compared to nevirapine (IC₅₀ = 6.29 µM). Interestingly, the conclusion did not apply to 7p–x which had oxygen atom on the C-2 side chain. On the contrary, 7p–x revealed better activities than 8p–x, such as 7q > 8q, 7r > 8r, 7t > 8t and 7w > 8w. Therefore, it was suggested that the oxygen atom might play a crucial role in the binding process with HIV-1 RT. In addition, substituting electron withdrawing groups at the para position of the phenyl ring at C-2 while increasing the length of side chain, would both be beneficial for the inhibitory activity, as exemplified by 7q > 7n > 7b, 8p > 8m > 8a, which were consistent with the previous work in our lab [16,17]. Meanwhile, taking 8n > 8o > 8m and 8q > 8r > 8p as examples, the activities were significantly improved by incorporating dimethyl and difluoro into the meta position of the C-6 aromatic moiety. According to the combined results, the target compounds 8h (IC₅₀ = 0.41 µM), 8l (IC₅₀ = 0.71 µM), 8n (IC₅₀ = 0.70 µM), 7q (IC₅₀ = 0.59 µM) had the best activities.

| Compd. | MW | EC₅₀ (µM)/SF33 | Compd. | MW | EC₅₀ (µM)/SF33 |
|--------|----|---------------|--------|----|---------------|
| 7n     | 395| 6.12          | 8n     | 521| 3.84          |
| 7q     | 411| 5.07          | 8q     | 537| 9.44          |
| 8h     | 504| 1.06          | 8r     | 545| 4.10          |
| NVP    | 265| 0.19          |        |    |               |

*a Nevirapine was used as reference compound.*

Subsequently, the anti-HIV-1 activity of some active compounds was determined using nevirapine as reference compound. As shown in Table 2, the target compounds were capable of inhibiting wild-type virus infection by HIV-1SF33 in TZM-bl cell line. Especially, 8h showed the moderate activity. Meanwhile, the inhibitory activity of 7n < 8n and 7q > 8q was consistent with that of the RT assay. Moreover, the anti-HIV-1 cytotoxicity of these compounds was also determined and CC₅₀ values above 80 µM were observed.

2.3. Computational Modeling

Furthermore, in order to explore the structure-activity relationships, docking simulations were performed using the ChemScore program. Some target compounds were flexibly docked into the binding site of HIV-1 RT (PDB entry1RT2, in complex with TNK-651) (Figure 3). Default parameters were set according to the ChemScore manual, unless otherwise specified [27]. The results displayed that these target compounds could form a hydrogen bond between N-3-H and the amino acid residues Lys101 of RT, which was necessary for the activity. The series of compounds 7a–o and 8a–o had similar binding modes as the complex of TNK-651/1RT2. Compared to 7a–o, 8a–o a iodo substituent at the C-5 position could form an extra bond with the carbonyl of Tyr181, which had a significant impact on the activity by increasing the interaction. However, when an oxygen atom was introduced on the C-2 side chain, it could give different results. Another hydrogen bond was formed between the oxygen atom and the Tyr318 of RT. The extra hydrogen bond could potentially function as a pivot point to change the conformation of the compound when binding to the NNBP. Therefore, 7p–x could interact more strongly with RT than 7a–o, which explained the observed increase of activity. Interestingly, as the conformation changed, the halogen bond at the C-5 position of 8p–x disappeared.
unexpectedly. Herein, by forming the additional hydrogen bond, bearing an oxygen on the C-2 side chain could obviously affect the SAR of the traditional S-DABOs analogues. Moreover, to a certain extent, extending the C-2 side chain for a better location at the same region as N-1 substituent of TNK-651 was beneficial for the anti-HIV activity. Introducing substituents such as nitro, cyano, acetyl and ester, to the \textit{para} position of the phenyl ring of the C-2 side chain, could significantly improve the inhibitory activity by forming another hydrogen bond with the Val106 residue. Meanwhile, because of the reduction in the electron density of the benzene ring with these electron withdrawing groups, a putative $\pi$-stacking interaction resulted with the electron rich benzene ring at the Tyr318 amino residue. In addition, due to the double or triple bonds in these groups, the well extended $\pi$-$\pi$ conjugated system could increase the possibility of forming interactions with amino acid residues Phe227, Pro236 and so on. Considering the C-6 position, when the phenyl ring was characterized by \textit{m}-dimethyl or \textit{m}-difluoro substituents, favorable $\pi$-stacking and $\pi$-$\sigma$ interactions would obviously be observed with the aromatic amino acid residues. Specifically, the dimethyl substituent could modulate the benzyl group into the most suitable conformation for the optimal affinity to the NNIBP by providing a special steric hindrance, where additional van der Waals contacts and $\pi$-$\sigma$ interactions might be observed with the conserved Trp229 and Phe227 residues. Introducing a difluoro substituent at the benzene ring could reduce its electron density, which was beneficial for a better interaction by producing the $\pi$-stacking interaction.

**Figure 3.** Binding mode of 8n (a), 8q (b) (blue) and TNK-651 (green) with HIV-1 RT. Hydrogen bonds are shown as a green dashed lines, and halogen bonds are shown as a green solid line.

3. Experimental

3.1. General Information

Melting points were measured on an X-4 apparatus and are reported without correction. NMR spectra were recorded on a Bruker AVANCE III-400 spectrometer with TMS as an internal standard and CDCl$_3$ or DMSO-$d_6$ as the solvents. The chemical shifts were expressed in parts per million (δ ppm). Coupling constants ($J$) were measured in Hz. MS were taken by Bruker Apex IV FTMS with methanol as the solvent. FTIR spectra were recorded in the solid state as KBr dispersions using a
Nicolet NEXUS 470 FTIR spectrometer. Silica gel H was used for the column chromatography and silica gel GF254 was used for TLC plates, which were used to monitor the reactions. CH3CN and acetone were dried with CaCl2, while other chemicals were purchased as reagent grade and used without further purification.

3.1.1. General Procedure for the Syntheses of Compounds 7a–r

6-Substitued benzyl-2-thioxouracil (compound 6, 0.47 mmol) and K2CO3 (0.94 mmol) were dissolved in DMSO (2 mL) and stirred at room temperature, then the corresponding substituted alkyl bromide (0.47 mmol) was added to the solution followed by stirring for 12 h. H2O (7 mL) was added and then the pH of solution was adjusted to 3 with 2 N hydrochloric acid. After the addition of ethyl acetate (10 mL), the solution was stirred for another 15 min. Ethyl acetate (20 mL × 3) was used to extract the aqueous layer and the organic phases were combined, dried over MgSO4 and concentrated under reduced pressure with a rotary evaporator. The crude product was purified with silica gel H, and EtOAc–petroleum ether was used as the eluting solvent, to yield the target products 7a–r.

2-(4-Nitrobenzylthio)-6-benzyluracil (7a). Yield: 62.61%. mp: 192–194 °C. 1H-NMR (DMSO-d6) δ: 3.77 (s, 2H, ArCH2), 4.40 (s, 2H, SCH2), 6.01 (s, 1H, 5-H), 7.19–7.29 (m, 5H, ArH), 7.47 (d, 2H, o-ArH, J = 8.4 Hz), 7.80 (d, 2H, m-ArH, J = 8.4 Hz). 13C-NMR (DMSO-d6) δ: 146.85, 138.33, 130.59, 129.69, 128.88, 126.94, 123.79 (C arom), 43.12 (SCH2), 32.83 (ArCH2). HRMS calcd. for C18H16N3O3S [M+H]+ 354.09069; found: 354.09007.

2-(4-Nitrobenzylthio)-6-(3,5-dimethylbenzyl)uracil (7b). Yield: 89.72%. mp: 218–220 °C. 1H-NMR (DMSO-d6) δ: 2.05 (s, 6H, Ar(CH3)2), 3.55 (s, 2H, (Me)2ArCH2), 4.27 (s, 2H, SCH2), 5.86 (s, 1H, 5-H), 6.70 (s, 3H, (Me)2ArH), 7.35 (d, 2H, o-ArH, J = 8.4 Hz), 8.03 (d, 2H, m-ArH, J = 8.4 Hz). 13C-NMR (DMSO-d6) δ: 162.28 (C-4), 159.86 (C-2), 158.00 (C-6), 149.79, 146.78, 138.14, 137.83, 130.58, 128.36, 127.39, 123.70 (C arom), 32.93 (SCH2), 30.21 (ArCH2), 21.28 (CH3). HRMS calcd. for C20H20N3O3S [M+H]+ 382.12199; found: 382.12142.

2-(4-Nitrobenzylthio)-6-(3,5-difluorobenzyl)uracil (7c). Yield: 73.05%. mp: 244–246 °C. 1H-NMR (DMSO-d6) δ: 3.79 (s, 2H, F2ArCH2), 4.42 (s, 2H, SCH2), 6.07 (s, 1H, 5-H), 6.93–7.06 (m, 3H, F2ArH), 7.52 (d, 2H, o-ArH, J = 8.4 Hz), 8.03 (d, 2H, m-ArH, J = 8.4 Hz). 13C-NMR (DMSO-d6) δ: 163.98 (C-4), 163.85 (C-F), 161.54 (C-2), 161.41 (C-6), 146.84, 146.68, 146.75, 130.39, 123.70, 112.86, 112.61 (C arom), 102.43 (C-5), 42.32 (SCH2), 33.07 (ArCH2). HRMS calcd. for C18H14F2N3O3S [M+H]+ 354.07184; found: 390.07125.

2-(4-Cyanobenzylthio)-6-benzyluracil (7d). Yield: 98.26%. mp: 190–193 °C. 1H-NMR (DMSO-d6) δ: 3.76 (s, 2H, ArCH2), 4.35 (s, 2H, SCH2), 6.00 (s, 1H, 5-H), 7.22–7.30 (m, 5H, ArH), 7.39 (d, 2H, o-ArH, J = 8.4 Hz), 7.61 (d, 2H, m-ArH, J = 8.4 Hz). 13C-NMR (DMSO-d6) δ: 144.62, 138.33, 132.59, 130.34, 129.67, 128.90, 126.98, 119.21 (C arom), 110.18 (CN), 43.18 (SCH2), 33.33 (ArCH2). HRMS calcd. for C19H16N3OS [M+H]+ 334.10086; found: 334.10041.

2-(4-Cyanobenzylthio)-6-(3,5-dimethylbenzyl)uracil (7e). Yield: 97.14%. mp: 193–196 °C. 1H-NMR (DMSO-d6) δ: 2.18 (s, 6H, Ar(CH3)2), 3.67 (s, 2H, (Me)2ArCH2), 4.37 (s, 2H, SCH2), 5.98 (s, 1H, 5-H),
Molecules 2014, 19 7111

6.83 (d, 3H, (Me)2ArH), 7.42 (d, 2H, o-ArH, J = 8 Hz), 7.60 (d, 2H, m-ArH, J = 8 Hz). 13C-NMR (DMSO-d6) δ: 144.65, 138.08, 137.813, 132.53, 130.34, 128.39, 127.39, 119.19 (C arom), 110.21 (CN), 43.08 (SCH2), 33.30 (ArCH2), 21.30 (CH3). HRMS calcd. for C21H20N3OS [M+H]+ 362.13216; found: 362.13153.

2-(4-Cyanobenzylthio)-6-(3, 5-difluorobenzyl)uracil (7f). Yield: 73.05%. mp: 205–208 °C. 1H-NMR (DMSO-d6) δ: 3.82 (s, 2H, F2ArCH2), 4.44 (s, 2H, SCH2), 6.70 (s, 1H, 5-H), 7.08–7.18 (m, 5H, ArH), 7.47 (d, 2H, o-ArH, J = 8.4 Hz), 7.66 (d, 2H, m-ArH, J = 8.4 Hz). 13C-NMR (DMSO-d6) δ: 164.00 (C-4), 163.86 (C–F), 161.55 (C-2), 161.42 (C-6), 144.52, 142.82, 132.52, 130.19, 119.17, 112.90, 112.66 (C arom), 110.26 (CN), 102.51 (C-5), 42.33 (SCH2), 33.32 (ArCH2). HRMS calcd. for C19H14F2N3OS [M+H]+ 370.08202; found: 370.08147.

2-(4-Acetylbenzylthio)-6-benzyluracil (7g). Yield: 83.10%. mp: 204–205 °C. 1H-NMR (DMSO-d6) δ: 2.38 (s, 3H, ArCOCH3), 3.65 (s, 2H, ArCH2), 4.23 (s, 2H, SCH2), 5.87 (s, 1H, 5-H), 7.08–7.18 (m, 5H, ArH), 7.23 (d, 2H, o-ArH, J = 8.4 Hz), 7.62 (d, 2H, m-ArH, J = 8.4 Hz). 13C-NMR (DMSO-d6) δ: 197.84 (CO), 144.00, 138.36, 136.05, 129.68, 129.64, 128.88, 128.69, 126.94 (C arom), 110.26 (CN), 102.51 (C-5), 42.33 (SCH2), 33.40 (ArCH2), 27.09 (CH3). HRMS calcd. for C20H19N2O2S [M+H]+ 351.11617; found: 351.11565.

2-(4-Acetylbenzylthio)-6-(3,5-dimethylbenzyl)uracil (7h). Yield: 85.18%. mp: 195–197 °C. 1H-NMR (DMSO-d6) δ: 2.23 (s, 6H, Ar(CH3)2), 2.54 (s, 3H, p-ArCOCH3), 3.73 (s, 2H, (Me)2ArCH2), 4.41 (s, 2H, SCH2), 6.01 (s, 1H, 5-H), 6.80 (s, 3H, (Me)2ArH), 7.41 (d, 2H, o-ArH, J = 7.2 Hz), 7.78 (d, 2H, m-ArH, J = 7.2 Hz). 13C-NMR (DMSO-d6) δ: 197.78 (CO), 150.27, 138.14, 137.82, 136.04, 126.94, 128.65, 128.38, 127.44 (C arom), 44.12 (SCH2), 43.15 (ArCH2), 27.06 (COCH3), 21.32 (CH3). HRMS calcd. for C22H23N2O2S [M+H]+ 379.14748; found: 379.14672.

2-(4-Acetylbenzylthio)-6-(3,5-difluorobenzyl)uracil (7i). Yield: 93.34%. mp: 251–254 °C. 1H-NMR (DMSO-d6) δ: 2.50 (s, 3H, ArCOCH3), 3.80 (s, 2H, F2ArCH2), 4.36 (s, 2H, SCH2), 6.05 (s, 1H, 5-H), 6.96–7.10 (m, 3H, F2ArH), 7.37 (d, 2H, o-ArH, J = 8 Hz), 7.76 (d, 2H, m-ArH, J = 8 Hz). 13C-NMR (DMSO-d6) δ: 197.75 (CO), 164.02 (C-4), 163.90 (C-F), 161.58 (C-2), 161.45 (C-6), 143.97, 142.88, 136.07, 129.50, 128.62, 112.95, 112.70 (C arom), 102.49 (C-5), 42.40 (SCH2), 33.39 (ArCH2), 27.04 (COCH3). HRMS calcd. for C20H17F2N2O2S [M+H]+ 387.09733; found: 387.09703.

2-(4-Methoxycarbonylbenzylthio)-6-benzyluracil (7j). Yield: 93.79%. mp: 214–217 °C. 1H-NMR (DMSO-d6) δ: 3.81 (s, 2H, ArCH2), 3.85 (s, 3H, ArCOOCH3), 4.40 (s, 2H, SCH2), 6.05 (s, 1H, 5-H), 6.96–7.10 (m, 3H, F2ArH), 7.37 (d, 2H, o-ArH, J = 8 Hz), 7.76 (d, 2H, m-ArH, J = 8 Hz). 13C-NMR (DMSO-d6) δ: 197.75 (CO), 164.02 (C-4), 163.90 (C-F), 161.58 (C-2), 161.45 (C-6), 143.97, 142.88, 136.07, 129.50, 128.62, 112.95, 112.70 (C arom), 102.49 (C-5), 42.40 (SCH2), 33.39 (ArCH2), 27.04 (COCH3). HRMS calcd. for C20H17F2N2O2S [M+H]+ 387.09733; found: 387.09703.

2-(4-Methoxycarbonylbenzylthio)-6-(3,5-dimethylbenzyl)uracil (7k). Yield: 90.91%. mp: 221–224 °C. 1H-NMR (DMSO-d6) δ: 2.06 (s, 6H, Ar(CH3)2), 3.55 (s, 2H, (Me)2ArCH2), 3.68 (s, 3H, p-ArCOCH3), 4.24 (s, 2H, SCH2), 5.84 (s, 1H, 5-H), 6.71 (s, 3H, (Me)2ArH), 7.23 (d, 2H, o-ArH, J = 8 Hz), 7.63 (d, 2H, m-ArH, J = 8 Hz). 13C-NMR (DMSO-d6) δ: 166.41 (CO), 144.30, 137.81, 129.71, 129.59, 128.74,
128.39, 127.43 (C arom), 52.52 (OCH$_3$), 43.13 (SCH$_2$), 33.34 (ArCH$_2$), 21.30 (CH$_3$). HRMS calcd. for C$_{22}$H$_{23}$N$_2$O$_3$S [M+H]$^+$ 395.14239; found: 395.14195.

2-(4-Methoxycarbonylbenzylthio)-6-(3,5-difluorobenzyl)uracil (7l). Yield: 70.71%. mp: 279–280 °C. $^1$H-NMR (DMSO-$d_6$) $\delta$: 3.79 (s, 2H, F$_2$ArCH$_2$), 3.80 (s, 3H, p-ArCO$_2$CH$_3$), 4.35 (s, 2H, SCH$_2$), 6.03 (s, 1H, 5-H), 6.97–7.07 (m, 3H, F$_2$ArH), 7.37 (d, 2H, o-ArH, $J = 8$ Hz), 7.77 (d, 2H, m-ArH, $J = 8$ Hz). $^{13}$C-NMR (DMSO-$d_6$) $\delta$: 166.40 (CO), 144.21, 142.93, 129.57, 128.80, 112.96, 112.71 (C arom), 52.54 (OCH$_3$), 42.38 (SCH$_2$), 33.38 (ArCH$_2$). HRMS calcd. for C$_{20}$H$_{17}$F$_2$N$_2$O$_3$S [M+H]$^+$ 403.09225; found: 403.09219.

2-(4-Nitrophenethylthio)-6-benzyluracil (7m). Yield: 84.14%. mp: 200–204 °C. $^1$H-NMR (DMSO-$d_6$) $\delta$: 3.01 (t, 2H, p-NO$_2$ArCH$_2$, $J = 7.2$ Hz), 3.34 (t, 2H, J 6.8Hz, SCH$_2$, $J = 7.2$ Hz), 3.80 (s, 2H, ArCH$_2$), 5.98 (s, 1H, 5-H), 7.20–7.32 (m, 5H, ArH), 7.43 (d, 2H, o-ArH, $J = 8$ Hz), 8.13 (d, 2H, m-ArH, $J = 8$ Hz). $^{13}$C-NMR (DMSO-$d_6$) $\delta$: 148.57, 146.64, 138.41, 130.32, 129.75, 128.71, 127.02, 123.87 (C arom), 43.10 (SCH$_2$), 35.11 (ArCH$_2$), 30.64 (NO$_2$ArCH$_2$). HRMS calcd. for C$_{19}$H$_{18}$N$_3$O$_3$S [M+H]$^+$ 368.10634; found: 368.10628.

2-(4-Nitrophenethylthio)-6-(3,5-dimethylbenzyl)uracil (7n). Yield: 50.20%. mp: 212–215 °C. $^1$H-NMR (DMSO-$d_6$) $\delta$: 2.02 (s, 6H, Ar(CH$_3$)$_2$), 2.88 (t, 2H, p-NO$_2$ArCH$_2$, $J = 7.2$ Hz), 3.34 (t, 2H, J 6.8Hz, SCH$_2$, $J = 7.2$ Hz), 3.80 (s, 2H, ArCH$_2$), 5.98 (s, 1H, 5-H), 7.20–7.32 (m, 5H, ArH), 7.43 (d, 2H, o-ArH, $J = 8$ Hz), 8.13 (d, 2H, m-ArH, $J = 8$ Hz). $^{13}$C-NMR (DMSO-$d_6$) $\delta$: 146.62, 137.73, 130.34, 128.32, 127.38, 123.85 (C arom), 46.63 (SCH$_2$), 35.01 (ArCH$_2$), 30.64 (NO$_2$ArCH$_2$). HRMS calcd. for C$_{21}$H$_{22}$N$_3$O$_3$S [M+H]$^+$ 396.13764; found: 396.13726. IR (KBr): 3433, 3114, 2917, 2852, 1646, 1605, 1522, 1459, 1346, 837, 756, 729 cm$^{-1}$.

2-(4-Nitrophenethylthio)-6-(3,5-difluorobenzyl)uracil (7o). Yield: 79.25%. mp: 220–222 °C. $^1$H-NMR (DMSO-$d_6$) $\delta$: 2.98 (t, 2H, p-NO$_2$ArCH$_2$, $J = 7.6$ Hz), 3.30 (t, 2H, J 6.8Hz, SCH$_2$, $J = 7.6$ Hz), 3.81 (s, 2H, ArCH$_2$), 6.02 (s, 1H, 5-H), 7.00–7.04 (m, 3H, F$_2$ArH), 7.41 (d, 2H, o-ArH, $J = 8$ Hz), 8.11 (d, 2H, m-ArH, $J = 8$ Hz). $^{13}$C-NMR (DMSO-$d_6$) $\delta$: 164.00 (C-4), 163.87 (C–F), 161.42 (C-6), 148.52, 146.64, 142.92, 130.28, 123.83, 112.96, 112.71 (C arom), 102.73 (C-5), 42.41 (SCH$_2$), 30.64 (NO$_2$ArCH$_2$). HRMS calcd. for C$_{19}$H$_{16}$F$_2$N$_3$O$_3$S [M+H]$^+$ 404.08749; found: 404.08743.

2-(2-(4-Nitrophenoxy)ethylthio)-6-benzyluracil (7p). Yield: 63.46%. mp: 212–213 °C. $^1$H-NMR (DMSO-$d_6$) $\delta$: 3.49 (t, 2H, p-NO$_2$ArCH$_2$), 3.76 (s, 2H, ArCH$_2$), 4.25 (t, 2H, SCH$_2$), 5.99 (s, 1H, 5-H), 7.18 (d, 2H, o-ArH, $J = 8$ Hz), 7.16–7.29 (m, 5H, ArH), 8.18 (d, 2H, m-ArH, $J = 8$ Hz). $^{13}$C-NMR (DMSO-$d_6$) $\delta$: 163.80 (CO), 141.46, 138.20, 129.62, 128.79, 126.90, 126.28, 115.47 (C arom), 67.30 (OCH$_2$), 42.87 (SCH$_2$), 28.76 (ArCH$_2$), 21.25 (CH$_3$). HRMS calcd. for C$_{19}$H$_{18}$F$_2$N$_3$O$_4$S [M+H]$^+$ 404.08749; found: 404.08743.

2-(2-(4-Nitrophenoxy)ethylthio)-6-(3,5-dimethylbenzyl)uracil (7q). Yield: 82.12%. mp: 210–214 °C. $^1$H-NMR (DMSO-$d_6$) $\delta$: 2.16 (s, 6H, Ar(CH$_3$)$_2$), 3.46 (t, 2H, SCH$_2$, $J = 6.4$ Hz), 3.65 (s, 2H, (Me)$_2$ArCH$_2$), 4.18 (t, 2H, OCH$_2$, $J = 6.4$ Hz), 5.95 (s, 1H, 5-H), 6.80 (d, 3H, (Me)$_2$ArH), 7.08 (d, 2H, o-ArH, $J = 9.2$ Hz), 8.15 (d, 2H, m-ArH, $J = 9.2$ Hz). $^{13}$C-NMR (DMSO-$d_6$) $\delta$: 163.78 (CO), 141.43,
138.00, 137.72, 128.32, 127.36, 126.27, 115.45 (C_arom), 67.22 (OCH2), 43.02 (SCH2), 28.84 (ArCH2), 21.25 (CH3). HRMS calcd. for C_{21}H_{22}N_{3}O_{4}S [M+H]^+ 412.13255; found: 412.13196. IR (KBr): 3433, 2920, 2851, 1648, 1595, 1546, 1513, 1465, 1345, 1266, 1027, 843, 751, 652 cm\(^{-1}\).

2-(2-(4-Nitrophenoxy)ethylthio)-6-(3,5-difluorobenzyl)uracil (7r). Yield: 82.76%. mp: 210–212 °C. 
\(^1\)H-NMR (DMSO-d\(_6\)) \(\delta\): 3.48 (t, 2H, SCH\(_2\), \(J = 6.4 \) Hz), 3.81 (s, 2H, F\(_2\)ArCH\(_2\)), 4.24 (t, 2H, OCH\(_2\), \(J = 6.4 \) Hz), 6.07 (s, 1H, 5-H), 6.99–7.02 (m, 3H, F\(_2\)ArH), 7.09 (d, 2H, o-ArH, \(J = 9.2 \) Hz), 8.18(d, 2H, m-ArH, \(J = 9.2 \) Hz). 13C-NMR (DMSO-d\(_6\)) \(\delta\): 163.94 (C-4), 163.78 (CO), 163.21 (C–F), 161.49 (C-2), 161.36 (C-6), 143.35, 142.76, 141.44, 126.27, 115.39, 112.92, 112.68 (C_arom), 102.43 (C-5), 67.24 (OCH\(_2\)), 43.29 (SCH\(_2\)), 28.90 (ArCH\(_2\)). HRMS calcd. for C\(_{19}\)H\(_{16}\)F\(_2\)N\(_3\)O\(_4\)S [M+H]^+ 420.08241; found: 420.08188.

3.1.2. General Procedure for the Syntheses of Compounds 7s–x

Sodium (6.43 mmol) was dissolved in anhydrous methanol (20 mL), 6-substituted benzyl-2-thiouracil (compound 6, 0.92 mmol) was added, followed by addition of the appropriate substituted alkyl halide (1.38 mmol). After completion of the reaction according to TLC analysis, the crude product were purified by silica gel column chromatography with EtOAc–petroleum ether as eluent to afford the white solid products 7s–x.

2-(Phenoxypropylthio)-6-benzyluracil (7s). Yield: 79.17%. mp: 89–91 °C. 
\(^1\)H-NMR (CDCl\(_3\)) \(\delta\): 2.11–2.17 (m, 2H, ArOCH\(_2\)CH\(_2\)), 3.36 (t, 2H, SCH\(_2\), \(J = 7.2 \) Hz), 3.79 (s, 2H, ArCH\(_2\)), 4.02 (t, 2H, ArOCH\(_2\), \(J = 7.2 \) Hz), 5.99 (s, 1H, 5-H), 6.89–7.33 (m, 10H, ArH). 13C-NMR (DMSO-d\(_6\)) \(\delta\): 158.85 (CO), 138.17, 129.95, 129.72, 128.78, 126.91, 121.03, 114.88 (C_arom), 66.51 (OCH\(_2\)), 43.16 (SCH\(_2\)), 29.27 (ArCH\(_2\)), 27.11 (CH\(_2\)). HRMS calcd. for C\(_{20}\)H\(_{21}\)N\(_2\)O\(_2\)S [M+H]^+ 353.13183; found: 353.13142.

2-(Phenoxypropylthio)-6-(3,5-dimethylbenzyl)uracil (7t). Yield: 64.57%. mp: 100–102 °C. 
\(^1\)H-NMR (CDCl\(_3\)) \(\delta\): 2.12–2.18 (m, 2H, ArOCH\(_2\)CH\(_2\)), 2.17 (s, 6H, Ar(CH\(_3\))\(_2\)), 3.35 (t, 2H, SCH\(_2\), \(J = 7.2 \) Hz), 3.69 (s, 2H, (Me\(_2\))ArCH\(_2\)), 4.01 (t, 2H, ArOCH\(_2\), \(J = 7.2 \) Hz), 5.96 (s, 1H, 5-H), 6.84–6.96 (m, 5H, ArH), 7.29 (d, 3H, (Me\(_2\))ArH). 13C-NMR (DMSO-d\(_6\)) \(\delta\): 158.97 (CO), 138.01, 137.74, 129.84, 128.32, 127.45, 121.02, 114.83 (C_arom), 66.21 (OCH\(_2\)), 43.17 (SCH\(_2\)), 28.76 (ArCH\(_2\)), 26.92 (CH\(_2\)), 21.38 (CH\(_2\)). HRMS calcd. for C\(_{22}\)H\(_{25}\)N\(_2\)O\(_2\)S [M+H]^+ 381.16313; found: 381.16260.

2-(Phenoxypropylthio)-6-(3,5-difluorobenzyl)uracil (7u). Yield: 62.14%. mp: 100–101 °C. 
\(^1\)H-NMR (CDCl\(_3\)) \(\delta\): 2.09–2.16 (m, 2H, ArOCH\(_2\)CH\(_2\)), 3.33 (t, 2H, SCH\(_2\), \(J = 7.2 \) Hz), 3.72 (s, 2H, F\(_2\)ArCH\(_2\)), 4.01 (t, 2H, ArOCH\(_2\), \(J = 7.2 \) Hz), 5.99 (s, 1H, 5-H), 6.67–7.30 (m, 8H, ArH). 13C-NMR (DMSO-d\(_6\)) \(\delta\): 163.91 (C-F), 161.02 (C-6), 158.78 (CO), 143.00, 129.81, 121.02, 114.83, 113.02, 102.57 (C_arom), 65.87 (OCH\(_2\)), 42.40 (SCH\(_2\)), 29.12 (ArCH\(_2\)), 27.27 (CH\(_2\)). HRMS calcd. for C\(_{20}\)H\(_{18}\)F\(_2\)N\(_3\)O\(_2\)S [M+H]^+ 389.11298; found: 389.11317.

2-(Benzyloxymethylthio)-6-benzyluracil (7v). Yield: 72.62%. mp: 118–120 °C. 
\(^1\)H-NMR (CDCl\(_3\)) \(\delta\): 3.82 (s, 2H, ArCH\(_2\)), 4.60 (s, 2H, ArCH\(_2\)O), 5.43 (s, 2H, SCH\(_2\)O), 5.99 (s, 1H, 5-H), 7.23–7.37 (m, 10H, ArH). 13C-NMR (DMSO-d\(_6\)) \(\delta\): 176.47 (C-4), 161.01 (C-2), 156.20 (C-6), 136.03, 129.53, 129.09,
2-(Benzylthio)methylthio)-6-(3,5-dimethylbenzyl)uracil (7w). Yield: 65.13%. mp: 134–136 °C. 1H-NMR (CDCl3) δ: 2.17 (s, 6H, Ar(CH3)2), 3.73 (s, 2H, ArCH2), 4.58 (s, 2H, ArCH2O), 5.42 (s, 2H, SCH2O), 5.98 (s, 1H, 5-H), 6.83 (d, 3H, (Me)2ArH), 7.26–7.35 (m, 5H, ArH). 13C-NMR (DMSO-d6) δ: 156.20 (C-6), 138.07, 137.73, 128.69, 128.38, 128.16, 128.11, 127.42, 127.23 (C arom), 103.73 (C-5), 71.72 (OCH2), 70.93 (SCH2), 37.13 (ArCH2), 21.16 (CH3). HRMS calcd. for C21H23N2O2S [M+H]+ 367.14748; found: 367.14662.

2-(Benzylthio)methylthio)-6-(3,5-difluorobenzyl)uracil (7x). Yield: 57.77%. mp: 120–122 °C. 1H-NMR (CDCl3) δ: 3.78 (s, 2H, F2ArCH2), 4.62 (s, 2H, ArCH2O), 5.42 (s, 2H, SCH2O), 6.03 (s, 1H, 5-H), 6.68 (d, 3H, F2ArH), 7.28–7.37 (m, 5H, ArH). 13C-NMR (DMSO-d6) δ: 176.47 (C-4), 163.59 (C-F), 161.34 (C-2), 154.78 (C-6), 140.83, 137.83, 128.73, 127.56, 112.98, 112.73, 102.53 (C arom), 104.55 (C-5), 71.79 (OCH2), 70.63 (SCH2), 36.49 (ArCH2). HRMS calcd. for C19H17F2N2O2S [M+H]+ 375.09733; found: 375.09789.

3.1.3. General Procedure for the Syntheses of Compounds 8a–u

Compound 7a–u (0.30 mmol) was dissolved in dry CH3CN (20 mL) and stirred at room temperature, then I2 (0.18 mmol) and Ce(NH4)2(NO3)6 (CAN, 0.18 mmol) were added to this solution followed by refluxing for 4 h. After cooling to room temperature, the reaction mixture was quenched with saturated aqueous NaHSO3 (15 mL). The CH3CN was evaporated under reduced pressure, and the residue was extracted with CH2Cl2 (20 mL × 3). The organic phases were combined, dried over MgSO4 and concentrated at reduced pressure with a rotary evaporator. The crude product was purified with silica gel H, and EtOAc–petroleum ether was used as the eluting solvent, to yield products 8a–u.

2-(4-Nitrobenzylthio)-5-iodine-6-benzyluracil (8a). Yield: 75.74%. mp: 207–210 °C. 1H-NMR (DMSO-d6) δ: 4.11 (s, 2H, ArCH2), 4.41 (s, 2H, SCH2), 7.24–7.30 (m, 5H, ArH), 7.45 (d, 2H, o-ArH, J = 8.4 Hz), 8.01 (d, 2H, m-ArH, J = 8.4 Hz). 13C-NMR (DMSO-d6) δ: 146.87, 146.47, 137.70, 130.49, 129.36, 128.93, 127.03, 127.88 (C arom), 46.41 (SCH2), 32.02 (ArCH2). HRMS calcd. for C18H15IN3O3S [M+H]+ 479.98733; found: 479.98704.

2-(4-Nitrobenzylthio)-5-iodine-6-(3,5-dimethylbenzyl)uracil (8b). Yield: 79.90%. mp: 224–228 °C. 1H-NMR (DMSO-d6) δ: 4.10 (s, 2H, F2ArCH2), 4.40 (s, 2H, ArCH2), 4.38 (s, 2H, SCH2), 7.24–7.30 (m, 5H, ArH), 7.45 (d, 2H, o-ArH, J = 8.4 Hz), 8.01 (d, 2H, m-ArH, J = 8.4 Hz). 13C-NMR (DMSO-d6) δ: 146.79, 146.53, 137.78, 137.50, 128.46, 128.46, 127.07, 123.66 (C arom), 46.56 (SCH2), 32.02 (ArCH2). HRMS calcd. for C20H19IN3O3S [M+H]+ 508.01863; found: 508.01826.

2-(4-Nitrobenzylthio)-5-iodine-6-(3,5-difluorobenzyl)uracil (8c). Yield: 69.81%. mp: 203–206 °C. 1H-NMR (DMSO-d6) δ: 4.10 (s, 2H, F2ArCH2), 4.40 (s, 2H, SCH2), 6.85–7.05 (m, 3H, F2ArH), 7.50 (d, 2H, o-ArH, J = 8.8 Hz), 8.04 (d, 2H, m-ArH, J = 8.8 Hz). 13C-NMR (DMSO-d6) δ: 163.85 (C-F), 146.83, 146.35, 142.00, 130.28, 123.68, 112.60, 112.35 (C arom), 102.51 (C-5), 47.78 (SCH2), 33.22 (ArCH2). HRMS calcd. for C18H13F2IN3O3S [M+H]+ 515.96849; found: 515.96792.
2-(4-Cyanobenzylthio)-5-iodine-6-benzyluracil (8d). Yield: 78.26%. mp: 223–226 °C. $^1$H-NMR (DMSO-$d_6$) $\delta$: 4.07 (s, 2H, ArCH$_2$), 4.34 (s, 2H, SCH$_2$), 7.21–7.29 (m, 5H, ArH), 7.35 (d, 2H, o-ArH, $J = 7.2$ Hz), 7.59 (d, 2H, m-ArH, $J = 7.2$ Hz), 13.05 (s, 1H, NH). $^{13}$C-NMR (DMSO-$d_6$) $\delta$: 144.26, 137.69, 132.55, 129.37, 128.89, 127.08, 118.76 (C$_{arom}$), 110.27 (CN), 46.79 (SCH$_2$), 33.18 (ArCH$_2$). HRMS calcd. for C$_{19}$H$_{15}$IN$_3$OS [M+H]+ 459.99750; found: 459.99747.

2-(4-Cyanobenzylthio)-5-iodine-6-(3,5-dimethylbenzyl)uracil (8e). Yield: 65.47%. mp: 224–227 °C. $^1$H-NMR (DMSO-$d_6$) $\delta$: 2.17 (s, 6H, Ar(CH$_3$)$_2$), 3.99 (s, 2H, (Me)$_2$ArCH$_2$), 4.35 (s, 2H, SCH$_2$), 6.83 (d, 3H, (Me)$_2$ArH), 7.36 (d, 2H, o-ArH, $J = 8$ Hz), 7.57 (d, 2H, m-ArH, $J = 8$ Hz). $^{13}$C-NMR (DMSO-$d_6$) $\delta$: 144.29, 137.76, 137.46, 132.51, 130.23, 128.48, 130.23, 128.48, 119.15 (C$_{arom}$), 110.25 (CN), 46.53 (SCH$_2$), 33.41 (ArCH$_2$), 21.34 (CH$_3$). HRMS calcd. for C$_{21}$H$_{19}$IN$_3$OS [M+H]+ 428.02880; found: 488.02855.

2-(4-Cyanobenzylthio)-5-iodine-6-(3,5-difluorobenzyl)uracil (8f). Yield: 82.17%. mp: 216–219 °C. $^1$H-NMR (DMSO-$d_6$) $\delta$: 4.06 (s, 2H, F$_2$ArCH$_2$), 4.32 (s, 2H, SCH$_2$), 6.83–7.08 (m, 3H, F$_2$ArH), 7.38 (d, 2H, o-ArH, $J = 8.4$ Hz), 7.60 (d, 2H, m-ArH, $J = 8.4$ Hz). $^{13}$C-NMR (DMSO-$d_6$) $\delta$: 163.83 (C-F), 161.52 (C-2), 161.38 (C-6), 144.09, 142.01, 132.50, 130.06, 119.12, 112.64, 112.39 (C$_{arom}$), 110.32 (CN), 102.56 (C-5), 46.12 (SCH$_2$), 33.49 (ArCH$_2$). HRMS calcd. for C$_{19}$H$_{13}$F$_2$IN$_3$OS [M+H]+ 495.97866; found: 495.97824.

2-(4-Acetylbenzylthio)-5-iodine-6-benzyluracil (8g). Yield: 86.51%. mp: 219–220 °C. $^1$H-NMR (DMSO-$d_6$) $\delta$: 2.52 (s, 3H, ArCOCH$_3$), 4.10 (s, 2H, ArCH$_2$), 4.35 (s, 2H, SCH$_2$), 7.24–7.30 (m, 5H, ArH), 7.34 (d, 2H, o-ArH, $J = 8$ Hz), 7.60 (d, 2H, m-ArH, $J = 8.4$ Hz). $^{13}$C-NMR (DMSO-$d_6$) $\delta$: 197.68 (CO), 143.45, 137.64, 135.89, 129.57, 129.39, 128.88, 128.70, 127.05 (C$_{arom}$), 46.45 (SCH$_2$), 33.44 (ArCH$_2$), 27.04 (CH$_3$). HRMS calcd. for C$_{20}$H$_{18}$IN$_2$O$_2$S [M+H]+ 477.01282; found: 477.01248.

2-(4-Acetylbenzylthio)-5-iodine-6-(3,5-Dimethylbenzyl)uracil (8h). Yield: 79.97%. mp: 201–203 °C. $^1$H-NMR (DMSO-$d_6$) $\delta$: 2.20 (s, 6H, Ar(CH$_3$)$_2$), 2.53 (s, 3H, p-ArCOCH$_3$), 4.10 (s, 2H, ArCH$_2$), 4.35 (s, 2H, SCH$_2$), 7.24–7.30 (m, 5H, ArH), 7.34 (d, 2H, o-ArH, $J = 8$ Hz), 7.60 (d, 2H, m-ArH, $J = 8$ Hz). $^{13}$C-NMR (DMSO-$d_6$) $\delta$: 197.68 (CO), 143.45, 137.64, 135.89, 129.57, 129.39, 128.88, 128.70, 127.05 (C$_{arom}$), 46.45 (SCH$_2$), 33.44 (ArCH$_2$), 27.04 (CH$_3$). HRMS calcd. for C$_{22}$H$_{22}$IN$_2$O$_2$S [M+H]+ 505.04412; found: 505.04325. IR (KBr): 3434, 2920, 2851, 1728, 1675, 1605, 1449, 1354, 1266, 1120, 836, 776, 638, 615 cm$^{-1}$.

2-(4-Acetylbenzylthio)-5-iodine-6-(3,5-Difluorobenzyl)uracil (8i). Yield: 88.79%. mp: 205–206 °C. $^1$H-NMR (DMSO-$d_6$) $\delta$: 2.53 (s, 3H, ArCOCH$_3$), 4.12 (s, 2H, F$_2$ArCH$_2$), 4.35 (s, 2H, SCH$_2$), 6.93–7.11 (m, 3H, F$_2$ArH), 7.35 (d, 2H, o-ArH, $J = 8$ Hz), 7.77 (d, 2H, m-ArH, $J = 8$ Hz). $^{13}$C-NMR (DMSO-$d_6$) $\delta$: 197.72 (CO), 164.00 (C-F), 161.54 (C-2), 161.41 (C-6), 143.59, 142.06, 136.05, 129.40, 128.60, 112.70, 112.45 (C$_{arom}$), 102.57 (C-5), 46.17 (SCH$_2$), 33.53 (ArCH$_2$), 27.02 (COCH$_3$). HRMS calcd. for C$_{20}$H$_{16}$F$_2$IN$_2$O$_2$S [M+H]+ 512.99397; found: 512.99383.

2-(4-Methoxycarbonylbenzylthio)-5-iodine-6-benzyluracil (8j). Yield: 92.59%. mp: 214–216 °C. $^1$H-NMR (DMSO-$d_6$) $\delta$: 3.85 (s, 3H, p-ArCOOCH$_3$), 4.12 (s, 2H, ArCH$_2$), 4.38 (s, 2H, SCH$_2$), 7.25–7.32 (m, 5H, ArH), 7.35 (d, 2H, o-ArH, $J = 7.6$ Hz), 7.78 (d, 2H, m-ArH, $J = 7.6$ Hz), 13.07 (s,
2-(4-Methoxy carbonyl benzylthio)-5-iodine-6-(3,5-dimethyl benzyl) uracil (8k). Yield: 80.18%. mp: 208–211 °C. H-NMR (DMSO-d₆) δ: 2.16 (s, 6H, Ar(CH₃)₂), 3.81 (s, 3H, p-ArCO₂CH₃), 4.01 (s, 2H, Me₂ArCH₂), 6.84 (s, 3H, Me₂ArH), 7.29 (d, 2H, o-ArH, J = 8 Hz), 7.72 (d, 2H, m-ArH, J = 8 Hz). C-NMR (DMSO-d₆) δ: 166.37 (CO), 143.95, 137.77, 129.60, 129.58, 128.78, 128.49, 127.13 (C arom), 52.54 (OCH₃), 46.60 (SCH₂), 33.46 (ArCH₂). HRMS calcd. for C₂₂H₂₂IN₂O₃S [M+H]+ 521.03903; found: 521.03770.

2-(4-Methoxy carbonyl benzylthio)-5-iodine-6-(3,5-difluorobenzyl) uracil (8l). Yield: 41.41%. mp: 210–213 °C. H-NMR (DMSO-d₆) δ: 3.81 (s, 3H, p-ArCO₂CH₃), 4.09 (s, 2H, F₂ArCH₂), 4.32 (s, 2H, SCH₂), 6.88–7.08 (m, 3H, F₂ArH), 7.32 (d, 2H, o-ArH, J = 8.4 Hz), 7.75 (d, 2H, m-ArH, J = 8.4 Hz). C-NMR (DMSO-d₆) δ: 166.34 (CO), 163.86 (C-F), 161.54 (C-2), 161.41 (C-6), 143.80, 142.08, 129.53, 129.46, 128.81, 128.46, 127.2 (C arom), 52.53 (OCH₃), 46.18 (SCH₂), 33.49 (ArCH₂). HRMS calcd. for C₁₉H₁₇F₂IN₃O₃S [M+H]+ 528.98889; found: 528.98826.

2-(4-Nitrophenethylthio)-5-iodine-6-(3,5-dimethyl benzyl) uracil (8n). Yield: 74.15%. mp: 220–221 °C. H-NMR (DMSO-d₆) δ: 2.17 (s, 6H, Ar(CH₃)₂), 2.25 (t, 2H, p-NO₂ArCH₂, J = 7.2 Hz), 3.00 (t, 2H, SCh₂, J = 7.2 Hz), 6.88–7.08 (m, 3H, ArH), 7.35 (d, 2H, o-ArH, J = 8.4 Hz), 8.10 (d, 2H, m-ArH, J = 8.4 Hz), 12.99 (s, 1H, NH). C-NMR (DMSO-d₆) δ: 148.36, 146.64, 137.87, 130.32, 129.28, 128.85, 127.02, 123.84 (C arom), 46.78 (SCh₂), 34.81 (ArCH₂), 30.86 (NO₂ArCH₂). HRMS calcd. for C₁₉H₁₇F₂IN₃O₃S [M+H]+ 529.98414; found: 529.98365.

2-(4-Nitrophenethylthio)-5-iodine-6-(2-(4-Nitrophenoxo)ethylthio) uracil (8p). Yield: 63.64%. mp: 204–205 °C. H-NMR (DMSO-d₆) δ: 3.44 (t, 2H, p-NO₂ArOCH₂, J = 6.4 Hz), 4.06 (s, 2H, ArCH₂), 4.16 (t, 2H, SCh₂, J = 6.4 Hz), 7.05 (d, 2H, o-ArH, J = 9.2 Hz), 7.16–7.29 (m, 5H, ArH), 8.16 (d, 2H, m-ArH,
2-(2-(4-Nitrophenoxy)ethylthio)-5-iodine-6-(3,5-dimethylbenzyl)uracil (8q). Yield: 60.48%. mp: 215–218 °C. 1H-NMR (DMSO-d6) δ: 2.16 (s, 6H, Ar(CH3)2), 3.42 (t, 2H, SCH2, J = 6.8 Hz), 6.81 (s, 2H, F2ArCH2), 4.18 (t, 2H, OCH2, J = 6.8 Hz), 6.81 (d, 3H, (Me)2ArH), 7.09 (d, 2H, o-ArH, J = 9.2 Hz), 8.15 (d, 2H, m-ArH, J = 9.2 Hz). 13C-NMR (DMSO-d6) δ: 163.72 (CO), 141.44, 137.68, 137.51, 128.41, 127.06, 126.23 (C arom), 115.39 (C-5), 67.02 (OCH2), 46.50 (SCH2), 29.18 (ArCH2), 21.31 (CH3). HRMS calcd. for C21H21IN3O4S [M+H]+ 538.02920; found: 538.02847. IR (KBr): 3433, 2920, 2851, 1633, 1596, 1554, 1513, 1464, 1347, 1258, 1231, 1030, 840, 750, 651, 596 cm⁻¹.

2-(2-(4-Nitrophenoxy)ethylthio)-5-Iodine-6-(3,5-difluorobenzyl)uracil (8r). Yield: 75.52%. mp: 224–226 °C. 1H-NMR (DMSO-d6) δ: 3.41 (t, 2H, SCH2, J = 6.4 Hz), 4.09 (s, 2H, F2ArCH2), 4.15 (t, 2H, OCH2, J = 6.4 Hz), 6.98 (d, 3H, F2ArH), 7.05 (d, 2H, o-ArH, J = 9.2 Hz), 8.16 (d, 2H, m-ArH, J = 9.2 Hz). 13C-NMR (DMSO-d6) δ: 163.92 (CO), 163.73 (C-F), 161.48 (C-2), 161.34 (C-6), 141.43, 126.23, 117.42, 114.79 (C-5), 66.51 (OCH2), 46.18 (SCH2), 29.07 (ArCH2), 27.39 (CH2). HRMS calcd. for C19H14F2IN3NaO4S [M+Na]+ 567.96100; found: 567.96056. IR (KBr): 3435, 2924, 2853, 1644, 1592, 1557, 1516, 1461, 1343, 1261, 1241, 1116, 1033, 851, 751, 656, 603 cm⁻¹.

2-(Phenoxypropylthio)-5-iodine-6-benzyluracil (8s). Yield: 68.26%. mp: 135–137 °C. 1H-NMR (CDCl3) δ: 1.95–2.00 (m, 2H, ArOCH2CH2), 3.19–3.20 (m, 2H, SCH2), 3.82–3.90 (m, 2H, ArOCH2), 4.10 (s, 2H, ArCH2), 6.58–7.51 (m, 10H, ArH). 13C-NMR (DMSO-d6) δ: 158.85 (CO), 138.43, 129.95, 129.44, 128.90, 127.01, 121.04, 117.70 (C arom), 114.79 (C-5), 66.51 (OCH2), 46.73 (SCH2), 29.07 (ArCH2), 27.39 (CH2). HRMS calcd. for C20H20IN2O2S [M+H]+ 479.02847; found: 479.02956.

2-(Phenoxypropylthio)-5-iodine-6-(3,5-dimethylbenzyl)uracil (8t). Yield: 60.11%. mp: 165–167 °C. 1H-NMR (CDCl3) δ: 2.04–2.11 (m, 2H, ArOCH2CH2), 2.27 (s, 6H, Ar(CH3)2), 3.27 (t, 2H, SCH2, J = 7.2 Hz), 3.93 (t, 2H, ArOCH2, J = 7.2 Hz), 4.08 (s, 2H, (Me)2ArCH2), 6.86–7.04 (m, 5H, ArH), 7.27 (q, 3H, (Me)2ArH). 13C-NMR (DMSO-d6) δ: 158.80 (CO), 138.37, 137.63, 129.80, 128.28, 127.09, 120.98, 117.65 (C arom), 114.35 (C-5), 66.21 (OCH2), 46.04 (SCH2), 29.13 (ArCH2), 27.26 (CH2), 21.38 (CH2). HRMS calcd. for C22H24IN2O2S [M+H]+ 507.05977; found: 507.06077.

2-(Phenoxypropylthio)-5-iodine-6-(3,5-difluorobenzyl)uracil (8u). Yield: 62.40%. mp: 156–158 °C. 1H-NMR (CDCl3) δ: 2.05–2.11 (m, 2H, ArOCH2CH2), 3.26 (t, 2H, SCH2, J = 7.2 Hz), 3.99 (t, 2H, ArOCH2, J = 7.2 Hz), 4.10 (s, 2H, F2ArCH2), 6.66–6.97 (m, 5H, ArH), 7.28 (q, 3H, F2ArH). 13C-NMR (DMSO-d6) δ: 161.62 (C-F), 160.28 (C-6), 158.52 (CO), 142.26, 129.56, 120.79, 112.32, 112.03, 102.25 (C arom), 114.73 (C-5), 65.47 (OCH2), 46.36 (SCH2), 29.11 (ArCH2), 27.69 (CH2). HRMS calcd. for C26H18F2IN2O2S [M+H]+ 515.00962; found: 515.01071.

3.1.4. General Procedure for the Syntheses of Compounds 8v–x

Compound 7v–u (0.10 mmol) and NIS (0.12 mmol) were dissolved in dry DMF (15 mL) after cooling to 0 °C of ice bath, then stirred to room temperature for another 10 h, the reaction
completed according to TLC analysis. The mixture was added to EtOAc (50 mL) and washed by saturated
brine (50 mL × 3). The organic phase was dried over MgSO₄ and concentrated at reduced pressure with
a rotary evaporator. The crude product was purified with silica gel H, and EtOAc–petroleum ether was
used as the eluting solvent, to yield products 8v–x.

2-(Benzyloxymethylthio)-5-iodine-6-benzyluracil (8v). Yield: 91.25%. mp: 133–135 °C. ¹H-NMR
(CDCl₃) δ: 4.14 (s, 2H, ArCH₂), 4.47 (s, 2H, ArCH₂O), 5.35 (s, 2H, SCH₂O), 7.15–7.33 (m, 8H, ArH).
¹³C-NMR (DMSO-d₆) δ: 175.23 (C-4), 160.50 (C-2), 156.39 (C-6), 138.60, 129.12, 129.06, 128.80,
128.45, 127.49, 127.43 (C_arom), 104.14 (C-5), 71.53 (OCH₂), 69.84 (SCH₂), 29.43 (ArCH₂). HRMS
calcd. for C₁₉H₁₈IN₂O₂S [M+H]⁺ 465.01282; found: 465.01307.

2-(Benzyloxymethylthio)-5-iodine-6-(3,5-dimethylbenzyl)uracil (8w). Yield: 78.90%. mp: 200–202 °C.
¹H-NMR (CDCl₃) δ: 2.20 (s, 6H, Ar(CH₃)₂), 4.07 (s, 2H, ArCH₂), 4.47 (s, 2H, ArCH₂O), 5.34 (s, 2H,
SCH₂O), 6.80–6.95 (m, 5H, ArH), 7.26–7.33 (m, 3H, (Me)₂ArH). ¹³C-NMR (DMSO-d₆) δ: 156.39 (C-6),
138.97, 137.49, 129.36, 129.02, 128.58, 128.06, 127.52, 126.96 (C_arom), 103.73 (C-5), 71.72 (OCH₂),
70.93 (SCH₂), 37.13 (ArCH₂), 21.16 (CH₃). HRMS calcd. for C₂₁H₂₂IN₂O₂S [M+H]⁺ 493.04412; found:
493.04508.

2-(Benzyloxymethylthio)-5-iodine-6-(3,5-difluorobenzyl)uracil (8x). Yield: 78.93%. mp: 196–198 °C.
¹H-NMR (CDCl₃) δ: 4.12 (s, 2H, F₂ArCH₂), 4.59 (s, 2H, ArCH₂O), 5.35 (s, 2H, SCH₂O), 6.63–6.90
(m, 3H, F₂ArH), 7.26–7.36 (m, 5H, ArH). ¹³C-NMR (DMSO-d₆) δ: 176.62 (C-4), 163.46 (C-F),
161.48 (C-2), 154.41 (C-6), 141.21, 138.27, 128.83, 127.77, 112.99, 111.94, 102.59 (C_arom), 105.25
(C-5), 72.22 (OCH₂), 70.92 (SCH₂), 35.53 (ArCH₂). HRMS calcd. for C₁₉H₁₆F₂IN₂O₂S [M+H]⁺
500.99397; found: 500.99365.

3.2. Biological Assays

3.2.1. Assay for Measuring the Inhibitory Activity of Compounds against HIV-1 RT

Oligo(dT) (TaKaRa Co., Otsu, Japan) was immobilized via its 5'-terminal phosphate to Covalink-
NH microtiter plates (NUNC Co., Roskilde, Denmark). The biotin-dUTP was incorporated by reverse
transcriptase (Sigma, St. Louis, MO, USA). Briefly, a serial concentration of inhibitor was added to the
mixture, which contained 50 mmol/L Tris-HCl (pH 8.3), 3 mmol/L MgCl₂, 75 mmol/L KCl, 5 mmol/L
DTT, 0.13 mg/mL BSA, 10 μg/mL poly (A), 0.75 μM biotin-11-Dutp, 1.5 μM dTTP and HIV-1 RT.
After incubation at 37 °C for 1h, washing buffer, which contained 50 mmol/L Tris-HCl (pH 7.5),
0.15 mol/L NaCl, 0.05 mmol/L MgCl₂ and 0.02% Tween20, was used to wash the plate. Then each
well of the plate was added 100 mL 1% BSA and incubated at room temperature for another 30 min.
The plate was washed with the same buffer for 3 times. Before further incubation at 37 °C for 1 h, 50 μL
of alkaline phosphatase streptavidin (SA-ALP) solution (100 ng/mL) was added to each well and
washed again as above. Finally, 50 μL of p-nitrophenyl phosphate, disodium (PNPP, 1 mg/mL, pH 9.5)
was added and incubated at 37 °C for 30 min. 0.5 mol/L NaOH was added to stop the reaction
and a colorimetric streptavidin-alkaline phosphatase reporter system was used to detect and quantify
the result.
3.2.2. Assay for Measuring the Inhibitory Activity of Compounds on HIV-1SF33 Infectious

TZM-bl cells, HIV-1$_{SF33}$ were obtained from the NIH AIDS Research and Reference Reagent Program (Germantown, MD, USA). The inhibitory activity of the compounds on infection by a laboratory-adapted HIV-1 strain SF33 was tested in TZM-bl cells. Briefly, TZM-bl cells (4 × 10$^4$/well) were infected by addition of 200 TCID$_{50}$ of HIV-1, followed by incubation for 2 h at 37 °C before addition of compounds at serial dilutions. After further incubation at 37 °C for 7 days, p24 was measured using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Vironostika HIV-1 Microelisa system; BioMérieux; Marcy l’Etoile, France). The concentration of a compound for inhibiting 50% viral replication (EC$_{50}$) was determined by nonlinear regression using GraphPad Prism 5.01.

3.3. Molecular Modeling

The docking studies were conducted by using software GOLD3.0.1 and protein crystal structures of wildtype RT/1 complex (PDB ID: 1RT2). Following the default settings of Chemscore in the software tool, top scored docked poses were visually inspected for each ligand in the DS 2.5 based on relevant molecules. The radius of the binding site sphere was defined by the original ligand as 8.9 Å, thus ensuring that the docking method was reliable.

4. Conclusions

In summary, a series of novel 2-arylalkylthio-5-iodine-6-substitutedbenzyl-pyrimidine-4(3H)-ones (S-DABOs) were synthesized as inhibitors of HIV-1 RT. We evaluated their anti-HIV activity on the HIV-1 RT and HIV-1$_{SF33}$ in TZM-bl cell lines. Biological results revealed that the target compounds displayed good activity. It was noteworthy that compounds bearing an oxygen atom on the C-2 side chain demonstrated a new SAR, and the differences in biological results seen between 7a–x and 8a–x were discussed. From this study, useful information was obtained for designing HIV-1 inhibitors with great efficiency and low toxicity.

Acknowledgments

We thank the Foundation of China (20972011, 21042009, 21172014) and grants from the Ministry of Science and Technology of China (2009ZX09301-010) for financial support.

Author Contributions

The listed authors contributed to this work as described in the following: J.L. and W.X. designed research; L.Z., X.T., Y.C., S.W., Y.Z., J.Z. and Y.G. performed research and analyzed the data; L.Z., C.T., Z.Z., J.L. and W.X. wrote the paper. All authors read and approved the final manuscript.

Conflicts of Interest

The authors declare no conflict of interest.
References

1. Rodgers, D.W.; Gamblin, S.J.; Harris, B.A.; Ray, S.; Culp, J.S.; Hellmig, B.; Woolf, D.J.; Debouck, C.; Harrison, S.C. The structure of unliganded reverse transcriptase from the human immunodeficiency virus type 1. *Proc. Natl. Acad. Sci. USA* 1995, 92, 1222–1226.

2. Ting, Z.; Lan, X. Progress in HIV non-nucleoside reverse transcriptase inhibitors (NNRTIs). *Acta Pharm. Sin.* 2004, 39, 666–672.

3. Mugnaini, C.; Manetti, F.; Este, J.A.; Clotet-Codina, I.; Maga, G.; Cancio, R.; Botta, M.; Corelli, F. Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors. *Bioorg. Med. Chem. Lett.* 2006, 16, 3541–3544.

4. Zhang, X. The newest developments in anti-HIV-1 drugs. *Acta Pharm. Sin.* 2010, 45, 194–204.

5. De Clercq, E. Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs): Past, Present, and Future. *Chem. Biodivers.* 2004, 1, 44–64.

6. Artico, M.; Massa, S.; Mai, A.; Marongiu, M.E.; Piras, G.; Tramontano, E.; la Colla, P. 3,4-Dihydro-2-alkoxy-6-benzyl-4-oxopyrimidines (DABOs): A new class of specific inhibitors of human immunodeficiency virus type 1. *Antivir. Chem. Chemother.* 1993, 4, 361–368.

7. Mai, A.; Artico, M.; Sbardella, G.; Massa, S.; Loi, A.G.; Scano, P.; la Colla, P. Preparation and anti-HIV-1 activity of Thio Analogues of Dihydroalkoxybenzyloxopyrimidines. *J. Med. Chem.* 1995, 38, 3258–3263.

8. Wang, Y.; Chen, F.; de Clercq, E.; Balzarini, J.; Pannecouque, C. Synthesis and *in vitro* anti-HIV evaluation of a new series of 6-arylmethyl-substituted S-DABOs as potential non-nucleoside HIV-1 reverse transcriptase inhibitors. *Eur. J. Med. Chem.* 2009, 44, 1016–1023.

9. Ragno, R.; Mai, A.; Sbardella, G.; Artico, M.; Musiu, C.; Mura, M.; Marceddu, T.; Cadieddu, A.; la Colla, P. Computer-aided design, synthesis, and anti-hiv-1 activity *in vitro* of 2-alkylamino-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as novel potent non-nucleoside reverse transcriptase inhibitors, also active against the Y181C variant. *J. Med. Chem.* 2004, 47, 928–934.

10. Esnouf, R.M.; Stuart, D.I.; de Clercq, E.; Schwartz, E.; Balzarini, J. Models which explain the inhibition of reverse transcriptase by HIV-1 specific (thio)carboxaanilide derivatives. *Biochem. Biophys. Res. Comm.* 1997, 234, 458–464.

11. Tantillo, C.; Ding, J.; Jacobo-Molina, A.; Nanni, R.G.; Boyer, P.L.; Hughes, S.H.; Pauwels, R.; Andries, K.; Janssen, P.A.; Arnold, E. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. *J. Mol. Boil.* 1994, 243, 369–387.

12. Meng, G.; Chen, F. Research progress of HEPT analogs as nonnucleoside HIV-1 reverse transcriptase inhibitors. *Chin. J. Med. Chem.* 2004, 14, 56–64.

13. Kohlstaedt, L.A.; Wang, J.; Friedman, J.M.; Rice, P.A.; Steits, T.A. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. *Science* 1992, 256, 1783–1790.

14. Das, K.; Lewi, P.J.; Hughes, S.H.; Arnold, E. Crystallography and the design of anti-AIDS drugs: Conformational flexibility and positional adaptability are important in the design of non-nucleoside HIV-1 reverse transcriptase inhibitors. *Prog. Biophys. Mol. Biol.* 2005, 88, 209–231.

15. He, Y.; Long, J.; Zhang, S.; Li, C.; Lai, C.; Zhang, C.; Li, D.; Zhang, D.; Wang, H.; Cai, Q.; et al. Synthesis and biological evaluation of novel dihydro-aryl/alkylsulfanyl-cyclohexylmethyl-
oxopyrimidines (S-DACOs) as high active anti-HIV agents. *Bioorg. Med. Chem. Lett.* **2011**, *21*, 694–697.

16. Qin, H.; Liu, C.; Guo, Y.; Wang, R.; Zhang, J.; Ma, L.; Zhang, Z.; Wang, X.; Cui, Y.; Liu, J. Synthesis and biological evaluation of novel C5 halogen-functionalized S-DABO as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. *Bioorg. Med. Chem.* **2010**, *18*, 3231–3237.

17. Wang, X.; Zhang, J.; Huang, Y.; Wang, R.; Zhang, L.; Qiao, K.; Li, L.; Liu, C.; Ouyang, Y.; Xu, W.; *et al*. Design, Synthesis and Biological Evaluation of 1-[(2-benzyloxyl/alkoxyl) methyl]-5-halo-6-aryluracils as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Improved Drug Resistance Profile. *J. Med. Chem.* **2012**, *55*, 2242–2250.

18. Davidson, D.; Berhardt, S.A. The Structure of Meldrum’s Supposed β-Lactonic Acid. *J. Am. Chem. Soc.* **1948**, *70*, 3426–3428.

19. Oikawa, Y.; Yoshika, T.; Sugano, K.; Yonemitsu, O. Methyl Phenylacetylelacetate from Phenylacetyl Chloride and Meldrum’s Acid. *Org. Synth.* **1985**, *63*, 198–202.

20. Danel, K.; Larsen, E.; Pedersen, E.B. Easy synthesis of 5,6-disubstituted acyclouridine derivatives. *Synthesis* **1995**, *8*, 934–936.

21. Mugnaini, C.; Alongi, M.; Togninelli, A.; Gevariya, H.; Rizzi, A.; Manetti, F.; Bernardini, C.; Angeli, L.; Tafi, A.; Bellucci, L.; *et al*. Dihydro- alkylthio- benzyl-oxopyrimidines as Inhibitors of reverse transcriptase: synthesis and rationalization of the biological data on both wild-type enzyme and relevant clinical mutants. *J. Med. Chem.* **2007**, *50*, 6580–6595.

22. Manetti, F.; Esté, J.A.; Clotet-Codina, I.; Armand-Ugon, M.; Maga, G.; Crespan, E.; Cancio, R.; Mugnaini, C.; Bernardini, C.; Togninelli, A.; *et al*. Parallel solution-phase and microwave-assisted synthesis of new s-dabo derivatives endowed with subnanomolar anti-hiv-1 activity. *J. Med. Chem.* **2005**, *48*, 8000–8008.

23. Qin, H.; Liu, C.; Guo, Y.; Zhang, J.; Zhang, S.; Zhang, Z.; Wang, X.; Zhang, L.; Liu, J. Synthesis and biological evaluation of novel 2-arylalkylthio-4-amino-6-benzyl pyrimidines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 3003–3005.

24. Asakura, J.; Robins, M.J. Cerium(IV)-Mediated Halogenation at C-5 of Uracil Derivatives. *J. Org. Chem.* **1990**, *55*, 4928–4933.

25. Yano, S.; Kazuno, H.; Suzuki, N.; Emura, T.; Wierzba, K.; Yamashita, J.; Tada, Y.; Yamada, Y.; Fukushima, M.; Asao, T. Synthesis and evaluation of 6-methylene-bridged uracil derivatives. Part 1: Discovery of novel orally active inhibitors of human thymidine phosphorylase. *Bioorg. Med. Chem.* **2004**, *12*, 3431–3441.

26. Lu, X.; Chen, Y.; Guo, Y.; Liu, Z.; Shi, Y.; Xu, Y.; Wang, X.; Zhang, Z.; Liu, J. The design and synthesis of N-1-alkylated-5-aminoarylalkylsubstituted-6-methyl uracils as potential non-nucleoside HIV-1 RT inhibitors. *Bioorg. Med. Chem.* **2007**, *15*, 7399–7407.

27. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. *J. Comput. Chem.* **1998**, *19*, 1639–1662.

Sample Availability: Samples of the compounds are not available from the authors.

© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).